Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

1.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

10.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.2K
Introduction to Hemostasis01:05

Introduction to Hemostasis

10.2K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
10.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

65
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
65
Coagulation01:09

Coagulation

8.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to 'Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk' [Journal of Thrombosis and Haemostasis. Volume 22, Issue 12, December 2024, Pages 3415-3430].

Journal of thrombosis and haemostasis : JTH·2026
Same author

Stuck on you: Tregs, αvβ8, TGF-β1, and platelets in ITP.

Blood·2026
Same author

Gynecologic and obstetric management of girls and women with von Willebrand disease.

Haematologica·2026
Same author

Impact of tranexamic acid on postpartum hemorrhage in type 1 von Willebrand disease treated with recombinant VWF.

Blood advances·2025
Same author

Take five: the story of factor V regulation.

Blood·2025
Same author

Targeted Treatment With Alpelisib for Papillary Intralymphatic Angioendothelioma Associated With Somatic PIK3CA Mosaicism.

Pediatric blood & cancer·2025

Related Experiment Video

Updated: Oct 24, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.7K

Hemophilia A (Factor VIII Deficiency).

Craig D Seaman1, Frederico Xavier2, Margaret V Ragni3

  • 1Department of Medicine, Division Hematology/Oncology, University of Pittsburgh Medical Center, 3636 Boulevard of the Allies, Pittsburgh, PA 15213-4306, USA.

Hematology/Oncology Clinics of North America
|August 14, 2021
PubMed
Summary

Advances in hemophilia A diagnosis and treatment include genetic testing for family planning and ultrasound for early bleed detection. Novel therapies and gene therapy offer improved quality of life and potential cures.

Keywords:
Gene therapyHemarthrosisInhibitorsNonfactor therapyUltrasoundprophylaxis

More Related Videos

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.5K
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.6K

Related Experiment Videos

Last Updated: Oct 24, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.7K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.5K
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.6K

Area of Science:

  • Hematology
  • Medical Genetics
  • Musculoskeletal Imaging

Background:

  • Hemophilia A management is evolving rapidly.
  • Traditional treatments pose challenges in administration and compliance.
  • Early diagnosis and intervention are crucial for preventing long-term complications.

Purpose of the Study:

  • To summarize recent advancements in hemophilia A diagnosis and management.
  • To highlight the impact of new technologies and therapies on patient care.

Main Methods:

  • Review of genetic testing techniques, including next-generation sequencing.
  • Discussion of musculoskeletal ultrasound for early detection of bleeds and joint disease.
  • Overview of novel therapeutic approaches, including gene therapy.

Main Results:

  • Genetic testing facilitates reproductive decision-making and prenatal diagnosis.
  • Musculoskeletal ultrasound enables prompt identification and management of bleeds and joint damage.
  • New therapies offer convenient administration (subcutaneous injections) and improved quality of life.
  • Gene therapy presents a potential one-time cure, though challenges like immune responses and toxicity exist.

Conclusions:

  • Modern diagnostic tools and novel therapies are transforming hemophilia A care.
  • These advancements promise better patient outcomes, improved quality of life, and potentially curative options.
  • Ongoing research addresses the complexities and long-term safety of gene therapy.